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ACE angiotensin converting enzyme
AT1 angiotensin II type 1 receptor
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AT2 angiotensin II type 2 receptor
cAMP cyclic adenosine 3',5'-monophosphate
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NO nitric oxide
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TGF-β1 transforming growth factor-β1
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8ABSTRACT
Cyclosporine A is an immunosuppressive drug widely used to prevent rejection of transplanted
organs and to treat autoimmune diseases. Cyclosporine A therapy is often limited by adverse effects
such as hypertension and nephrotoxicity. Cyclosporine A nephrotoxicity is characterised by renal
dysfunction and by renal morphological damage with interstitial fibrosis and arteriolopathy. The
exact mechanisms of cyclosporine A-induced hypertension and nephrotoxicity are unknown.
Renal and cardiovascular effects of long-term administration of cyclosporine A were studied in
spontaneously hypertensive rats on high-sodium diet. The animal model was selected to overcome
the resistance of normotensive rats to adverse renal and cardiovascular effects of cyclosporine A.
The role of the renin-angiotensin system, the renal kallirein-kinin system, the L-arginine−nitric
oxide pathway and oxidative stress in cyclosporine A-induced renal and cardiovascular toxicity
were evaluated. Furthermore, the effects of cyclosporine A on arterial function and structure were
examined.
Six-weeks administration of cyclosporine A caused hypertension and nephrotoxicity in
spontaneously hypertensive rats in the developmental phase of hypertension. Cyclosporine A-
induced hypertension and nephrotoxicity were related to vascular dysfunction, which was more
pronounced in renal than in mesenteric arteries. The vascular dysfunction included both impaired
endothelium-dependent (acetylcholine) and endothelium-independent (sodium-nitroprusside)
relaxations as well as decreased contractile responses to noradrenaline, potassium chloride and
angiotensin II. Cyclosporine A also caused morphological damage to intrarenal arterioles and small
arteries and, to a lesser extent, mesenteric resistance vessels. Long-term cyclosporine A
administration decreased aortic smooth muscle cell viability in cell cultures.
Cyclosporine A caused a rise in plasma renin activity, but did not affect urinary cyclic guanosine
3',5'-monophosphate, kallikrein or 8-isoprostaglandin F2α excretion. Neither did it affect endothelial
or inducible nitric oxide synthase expression in the kidney, heart or aorta nor plasma total radical
trapping parameter or urate concentration. Concomitant inhibition of the renin-angiotensin system
with angiotensin converting enzyme inhibitor enalapril or with angiotensin AT1 receptor antagonist
valsartan protected against cyclosporine A toxicity. Bradykinin B2 receptor antagonist icatibant
9(HOE 140) did not reduce the beneficial effects of enalapril. The precursor of nitric oxide, L-
arginine, did not markedly affect cyclosporine A-induced hypertension, renal dysfunction or
morphological damage to kidneys or vessels. L-arginine did, however, tend to improve arterial
dysfunction in spontaneously hypertensive rats treated with cyclosporine A.
These results suggest that the activation of the renin-angiotensin system plays an important part in
cyclosporine A toxicity in this hypertensive animal model. Inhibition of the renin-angiotensin
system by angiotensin converting enzyme inhibitor or by AT1 receptor antagonist is effective in
protecting against renal and cardiovascular toxicity of cyclosporine A. In contrast, these studies
indicate no role for the renal kallikrein-kinin system, the L-arginine−nitric oxide pathway or
oxidative stress as primary mediators of cyclosporine A toxicity. However, the participation of these
mechanisms cannot be totally excluded.
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1. INTRODUCTION
Cyclosporine A (CsA) is an immunosuppressive drug widely used to prevent rejection of
transplanted organs and to treat autoimmune diseases. CsA treatment is often limited by adverse
effects such as hypertension and nephrotoxicity (for review, see Andoh and Bennett 1998; Taler et
al. 1999). CsA nephrotoxicity is characterised by renal dysfunction as evidenced by a rise in serum
creatinine and a decrease in creatinine clearance and by morphological damage with interstitial
fibrosis and arteriolopathy (Andoh and Bennett 1998).
The exact mechanisms of CsA-induced hypertension and nephrotoxicity remain obscure. Clinical
and experimental studies have revealed that several mechanisms may be involved (Table 1). These
include activation of the renin-angiotensin system (RAS) (Murray et al. 1985; Edwards et al. 1994;
Burdmann et al. 1995; Shihab et al. 1996), enhanced sympathetic tone (Murray et al. 1985) or
increased synthesis of endothelins (Fogo et al. 1992; Lanese and Conger 1993). Use of CsA is also
reported to be related to increased vasoconstriction (Murray et al. 1985) and vascular endothelial
dysfunction (De Nicola et al. 1993; Amore et al. 1995; Stephan et al. 1995). The renal and
cardiovascular effects may be related to reduced prostacyclin (PGI2) production (Neild et al. 1983),
increased thromboxane synthesis (Perico et al. 1986), transforming growth factor-β expression
(TGF-β1) (Wolf et al. 1995) or leukotriene production (Butterly et al. 2000). Some studies suggest a
defect in intracellular calcium handling (Lo Russo et al. 1996), magnesium deficiency (Mervaala et
al. 1997), decreased renal dopamine production (Pestana et al. 1995), induction of cytochrome P450
isoenzymes in renal microsomes (Basu et al. 1994; Nakamura et al. 1994), oxidative stress (De
Nicola et al. 1993) or rise in serum cholesterol level (Satterthwaite et al. 1998) as possible
mechanisms of renal and cardiovascular effects of CsA. Finally, a renal defect in sodium handling
may participate in the CsA toxicity (Curtis et al. 1988; Curtis 1994).
Many of the clinically seen adverse effects of CsA have been difficult to produce in animals.
Sodium-depleted normotensive Sprague Dawley rats have been used to study the nephrotoxicity of
CsA (Burdmann et al. 1995; Pichler et al. 1995; Porter et al. 1999). In this rat model, a fairly high
dose of CsA (15 mg/kg/day s.c.) causes morphologically similar renal toxicity, mainly characterised
by tubulointerstitial fibrosis of striped pattern and arteriolopathy of the afferent arterioles, to that
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Table 1. Proposed mechanisms of cyclosporine A-induced renal and cardiovascular toxicity.
Mechanism Reference
activation of the renin-angiotensin system Murray et al. 1985; Edwards et al. 1994;
Burdmann et al. 1995; Shihab et al. 1996
vasoconstriction Murray et al. 1985; Epstein et al. 1998
defect in intracellular calcium handling Lo Russo et al. 1996; Avdonin et al. 1999
endothelial dysfunction De Nicola et al. 1993; Amore et al. 1995;
Stephan et al. 1995
increased endothelin synthesis Fogo et al. 1992; Lanese and Conger 1993
reduced prostacyclin production Neild et al. 1983
increased tromboxane production Perico et al. 1986
increased leukotriene production Butterly et al. 2000
decreased dopamine synthesis Pestana et al. 1995
oxidative stress De Nicola et al. 1993
induction of cytochrome P450 isoenzymes Nakamura et al. 1994
enhanced sympathetic tone Murray et al. 1985; Scherrer et al. 1990
renal defect in sodium handling Curtis et al. 1988; Curtis 1994
induction of transforming growth factor-β1 Wolf et al. 1995
magnesium deficiency Mervaala et al. 1997
changes in serum cholesterol level Satterthwaite et al. 1998
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2. REVIEW OF THE LITERATURE
2.1. General aspects of cyclosporine A
CsA is a cyclic endecapeptide which is derived from extracts of Tolypocladium inflatium Gams, a
member of the Fungi imperfekti family (Figure 1) (Kahan 1999).
''The high treeless plain where this fungus was discovered, Hardarger Vidda, is a land
populated by malevolent spirits. One man, Askelad, a Nordic folk hero, used his
ingenuity and perseverance to subvert the spirits’ schemes and preserve the peace and
harmony of the community'' (Kahan 1999).
Since the early 1980’s, CsA has been widely used to prevent rejection of organ transplants. It has
increased graft survival and decreased patient mortality (Kahan et al. 1987; 1999). The use of CsA
to treat autoimmune diseases has increased during recent years (Bach 1999). In Finland, indications
of CsA include rheumatoid arthritis, psoriasis, atopic dermatitis, endogenous uveitis and nephrotic
syndrome. The dose of CsA in autoimmune diseases is usually lower than that used in organ
transplantations (Bach 1999). Unlike in organ transplantations, in autoimmune diseases the use of
CsA is often temporary.
CsA was the first T-lymphocyte selective drug to inhibit lymphocyte function without concomitant
myelosuppression. CsA binds to cyclophilin to inhibit phosphatase calcineurin, and thereby prevents
the dephosphorylation of nuclear factor of activated T-cells that is essential for upregulation of
messenger ribonucleic acid (mRNA) (Figure 2) (Liu et al. 1992). Thus, CsA interferes with the
synthesis of many lymphokine mediators, particularly interleukin-2, which is critical for T-
lymphocyte proliferation and maturition, and interferon-γ, which is critical for macrophage
activation. It has recently been proposed that increased production of TGF-β1 is at least partly
responsible for the immunosuppressive effects of CsA (Hojo et al. 1999; Nabel 1999). The
mechanism for the induction of TGF-β1 by CsA remains obscure (Nabel 1999).
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The extent to which the adverse effects of CsA are related to the immunosuppressive mechanisms
of the drug is controversial. Inhibition of calcineurin by CsA may alter the production of many
biologically active agents, such as endothelin, NO and TGF-β1, which have been implicated in
adverse renal and cardiovascular effects (Curtis 1998; Hemenway and Heitman 1999). On the other
hand, calcineurin inhibition may protect against the development of left ventricular hypertrophy
(Sussman et al. 1998).
CsA
CsA-cyclophillin
Calcineurin
NF-ATp NF-AT
Interleukin-2
Stimulation of 
immune response
Plasma membrane
Nuclear membrane
Figure 2. Main mechanism for the immunosuppressive action of cyclosporine. CsA, cyclosporine;
NF-AT, nuclear factor of activated T-cells; p, phosphate group. Adapted from Nabel (1999).
2.2.  Adverse renal and cardiovascular effects of cyclosporine A
 
2.2.1.  Human studies
The most important adverse effects that restrict the use of CsA are nephrotoxicity and hypertension
(Mason 1989; Taler et al. 1999). These effects have been detected in transplant recipients and in
autoimmune patients. Other factors besides CsA may, however, also contribute to these
abnormalities, and thus, determining the effects of CsA alone is difficult. In transplant patients,
these confounding factors include rejection of the transplanted organ and concomitant
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glucocorticoid and other immunosuppressive treatments. In some autoimmune patients, for example
those suffering from rheumatoid arthritis, the disease itself may cause renal and cardiovascular
sequalae (Bach 1999).
A single dose of CsA causes a transient rise in blood pressure in healthy volunteers (Hansen et al.
1997). Long-term CsA treatment in organ transplant recipients increases the risk for hypertension
compared with the therapy with azathioprine and glucocorticoids (Kahan et al. 1987; Schorn et al.
1988; Taler et al. 1999). CsA also induces hypertension in autoimmune patients (Bach 1999). While
the incidence of hypertension is 29−54% in CsA-treated autoimmune patients, in transplant patients
the corresponding figure is 71−100% (Taler et al. 1999). Hypertension is an independent risk factor
for atherosclerosis in CsA-treated transplant patients (Kasiske 1988). Furthermore, hypertension
after transplantation is related with lower rates of graft survival (van Ypersele de Strihou et al.
1983). Hypertension is usually reversible after discontinuation of short-term CsA therapy (Taler et
al. 1999), whereas continued treatment even at reduced doses frequently results in sustained
hypertension (Schwartz et al. 1996).
Adverse renal effects of CsA can be divided into two categories: functional and histological
abnormalities. CsA-induced renal dysfunction is related to reduced glomerular filtration rate and
renal blood flow. This is generally thought to be secondary to vasoconstriction of the glomerular
afferent arterioles, which causes a decrease in glomerular pressure (Murray et al. 1985; Myers et al.
1988; Hansen et al. 1997; Andoh and Bennett 1998). Renal dysfunction, in turn, causes an increase
in serum creatinine concentration and a decrease in creatinine clearance. These functional changes
are dose-dependent and are usually reversible after short-term CsA treatment (Andoh and Bennett
1998).
CsA-induced histological renal damage is mainly characterised by tubulointerstitial fibrosis of
striped pattern and arteriolopathy of the afferent arterioles (Antonovych et al. 1988; Mihatsch et al.
1988; Andoh and Bennett 1998). Interstitial fibrosis consists of streaks of fibrosis. Arteriolopathy is
characterised by luminal narrowing and arteriolar wall thickening. These changes are composed of
subendothelial edema, swelling of hypertrophied endothelial cells protruding into the lumen and
eosinophilic granular transformation of vascular smooth muscle cells. However, other types of renal
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lesions, including glomerular and tubular damage, have also been linked with CsA treatment
(Antonovych et al. 1988; Andoh and Bennett 1998). The histological changes develop mainly
during long-term use and are usually irreversible once established even if CsA treatment is ceased,
but the risk of histological changes is diminished with reducing the dose of CsA (Andoh and
Bennett 1998).
2.2.2. Animal studies
As a consequence of the resistance of rats to adverse renal and cardiovascular effects of CsA, there
was very little if any preclinical information on them in early clinical use (for review, see Curtis
1994). Therefore, the adverse renal and cardiovascular effects of CsA were somewhat unexpected.
A great deal of effort was put into developing suitable animal models to study the mechanisms of
these CsA-induced abnormalities.
The adverse renal effects of CsA were slight or absent in normotensive rats on normal-sodium diet
(Elzinga et al. 1993; Porter et al. 1999). An exception to this was that CsA in a year-long study
induced tubulointerstitial fibrosis (Lafayette et al. 1993). To study the nephrotoxicity of CsA, a rat
model using sodium-depleted normotensive Sprague Dawley rats was developed (Burdmann et al.
1995; Pichler et al. 1995; Young et al. 1995b; Porter et al. 1999). In this rat model, a fairly high
dose of CsA (15 mg/kg/day s.c.) for four weeks caused morphological and functional renal toxicity
similar to that seen in CsA-treated patients.
According to several studies, CsA does not induce hypertension in normotensive rats even if high
doses of up to 50 mg/kg/day are used (Nahman et al. 1988; Diederich et al. 1992; Lafayette et al.
1993; Basu et al. 1994; Stephan et al. 1995). A moderate rise in blood pressure by CsA at 25
mg/kg/day has, however, been reported in some studies of normotensive rats (Takeda et al. 1995;
Oriji and Keiser 1998). The SHR model is a well-known genetic hypertension model that has many
similarities to human essential hypertension (Okamoto et al. 1964; Phillips 1999). A few previous
studies of CsA with SHR have been reported. Interestingly, CsA at a dose of 10 mg/kg/day delayed
the onset of hypertension in two-week-old SHR (Sitsen and de Jong 1987). In SHR in the
developmental phase of hypertension, CsA at doses of 20−100 mg/kg/day induced elevation of
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blood pressure and renal vascular lesions (Ryffel et al. 1986; Nahman et al. 1988). At 5 mg/kg/day,
CsA caused a rise in blood pressure on normal-sodium diet (Basu et al. 1994; Mervaala et al. 1997).
On high-sodium diet in SHR, CsA-induced hypertension manifests with concomitant renal
dysfunction and glomerular damage (Mervaala et al. 1997; Pere et al. 1998).
2.3.  Mechanisms of cyclosporine A toxicity
 
2.3.1.  Renin-angiotensin system and kallikrein-kinin system
2.3.1.1. Renin-angiotensin system in control of cardiovascular functions
The renin-angiotensin system (RAS) is an important regulator of blood pressure and renal function.
The most important effector of RAS is octapeptide angiotensin II (Figure 3). It is formed in an
enzyme cascade initiated by renin, which is secreted from juxtaglomerular cells of the kidney.
While RAS is a circulatory hormone system, all of its components also exist locally in tissues, e.g.
in the kidney, blood vessel wall, heart, brain and adrenal cortex (for review, see Ganten et al. 1983;
Kim and Iwao 2000). Therefore, RAS seems to be a regional regulator as well.
The main stimulators of renin release are decreased sodium concentration in the distal tubule,
decreased renal perfusion pressure and adrenergic β1-receptor stimulation. Angiotensin II,
potassium, antidiuretic hormone and atrial natriuretic peptide reduce renin release. Renin cleaves
angiotensinogen, which is derived from the liver, into inactive decapeptide angiotensin I (Kim and
Iwao 2000).
There are different enzymatic routes of angiotensin II formation from angiotensin I (Figure 3).
Angiotensin I is activated by angiotensin converting enzyme (ACE), which is mainly located on the
surface of the vascular endothelium and the lung epithelium. Other enzymes, including chymase,
which is present in the heart, can also convert angiotensin I to angiotensin II. The importance of
these non-ACE-pathways is still controversial. In humans, the non-ACE pathways are reported to
represent at least 40% of total angiotensin II formation (Hollenberg et al. 1998). Some evidence
exists that ACE-independent pathways become quantitatively more important under pathological
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conditions such as diabetes (Hollenberg et al. 1998). In rats, however, ACE seems to be the most
important enzyme for angiotensin II formation (Okunishi et al. 1993).
Angiotensinogen
Angiotensin I
Angiotensin II
Renin
ACE
=
kininase II
t-PA
Cathepsin G Chymase
CAGE
Bradykinin
Degradation products
Kininogen
Kallikrein
AT1 receptor AT2 receptor
zVasoconstriction
zEndothelin production
zSuperoxide production
zSympathetic activation
zAldosterone release
zSodium and water retention 
zCellular growth ↑
zVasodilatation
zCellular growth ↓
zApoptosis
B2 receptorB1 receptor
zVasodilatation
zNO production
zProstaglandin 
production
zNatriuresis
zVasoconstriction
Figure 3.
 Renin-angiotensin system and kallikrein-kinin system. ACE, angiotensin converting
enzyme; CAGE, chymostatin-sensitive angiotensin II-generating enzyme; NO, nitric oxide;
t-PA, tissue plasminogen activator.
At least two types of angiotensin receptors are present on the surface of the target cells: Angiotensin
II type 1 (AT1) and type 2 (AT2) receptors (for review, see Stroth and Unger 1999). AT1 receptors
can be further sudivided into subtype A (AT1A) and subtype B (AT1B) receptors. AT1A receptor is the
major subtype mediating cardiovascular and renal effects of angiotensin II (Llorens-Cortes et al.
1994). AT1 receptors are G-protein-coupled receptors with several second-messenger systems,
including activation of phospholipase C. This results in activation of the phosphoinositol pathway,
which leads to increased intracellular calcium levels and protein kinase C activation. These, in turn,
activate growth-related immediate transcription factors, such as c-fos, c-myc and c-jun.
Furthermore, inhibition of adenylate cyclase by angiotensin II reduces cyclic adenosine 3', 5'-
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monophosphate (cAMP) levels. AT2 receptors are also coupled to G-proteins, but the signal
transduction pathways are not fully known (Stroth and Unger 1999).
Most of the known cardiovascular effects of angiotensin II are mediated via AT1 receptors. These
include contraction of vascular smooth muscle, enhancement of calcium sensitivity of the
contractile apparatus of the smooth muscle, increased endothelin production, facilitation of
noradrenaline biosynthesis and release and inhibition of its reuptake in sympathetic nerve terminals,
stimulation of catecholamine release from the adrenal medulla, positive inotropic and chronotropic
action on the heart and facilitation of aldosterone biosynthesis and secretion in the adrenal cortex.
Furthermore, AT1 receptor stimulation augments tubular sodium reabsorption in the kidney, inhibits
renin release, induces polydipsia and releases vasopressin from the pituitary gland (for review, see
Stroth and Unger 1999; Kim and Iwao 2000).
Growing evidence shows that AT2 receptors are also important in controlling the cardiovascular
system (for review, see Stroth and Unger 1999). It seems that most of the effects mediated by AT2
receptors are the opposite of those mediated by AT1. AT2 receptor knock-out mice develop an
increase in blood pressure and an increased sensitivity to the pressor actions of angiotensin II (Ichiki
et al. 1995). The stimulation of AT2 receptors is proposed to antagonise the AT1-mediated blood
pressure increase (Scheuer and
 
Perrone 1993), to cause vasodilation and an inhibition of
angiogenesis (Munzenmaier and Greene 1996) and to increase endothelial NO production (Seyedi et
al. 1995). In vitro evidence shows that stimulation of AT2 receptors may cause apoptosis of cells
(Yamada et al. 1996). However, it seems that both receptor subtypes can mediate vascular apoptosis
in rats in vivo (Diep et al. 1999).
Even though RAS has an important role in regulating blood pressure, its role in hypertension is
unclear. In some renovascular  forms of hypertension, activation of RAS is the major reason for the
development of hypertension. Otherwise, increased activity of RAS, measured as plasma renin
activity (PRA) elevation or as increased plasma angiotensin II concentrations, is an irregular finding
in SHR or in human essential hypertension (Paran et al. 1995). However, antagonism of RAS by
ACE inhibitors and AT1 receptor antagonists is effective in reducing blood pressure in SHR and in
hypertensive patients (Timmermans and Smith 1996; Gavras 1997).
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Moreover, angiotensin II may play a role in the development of renal and vascular damage
independently of blood pressure. Via AT1 receptors, angiotensin II can cause cell growth,
differentiation and proliferation directly by affecting several kinase pathways and indirectly by
inducing several growth factors, including TGF-β1 and platelet-derived growth factor (for review,
see Stroth and Unger 1999).
2.3.1.2. Kallikrein-kinin system in control of cardiovascular functions
The kallikrein-kinin system plays a role in controlling blood pressure, renal haemodynamics and
excretory functions (for review, see Majima and Katori 1995). Tissue and plasma kallikreins
generate kinins from kininogens by hydrolysis (Figure 3). Kinins are oligopeptides that contain the
bradykinin sequence in their structure. There are two types of bradykinin receptors, B1 and B2
receptors. G-protein-coupled B2 receptors mediate most of the known effects of bradykinin. The
activation of B2 receptors causes phospholipase C activation and thus an increase in intracellular
calcium concentration which stimulates the production of NO and vasoactive prostanoids such as
prostaglandin E2 (PGE2) and PGI2. (Linz et al. 1995). The effects mediated via B1 receptors are not
well known, but recent evidence suggests that activation of these receptors results in
vasoconstriction and decreased glomerular filtration rate (Schanstra et al. 2000). The expression of
B1 receptors is reported to be induced during inflammation in rats (Schanstra et al. 2000) and in
renal disease in patients (Naicker et al. 1999). Kinins are destroyed by kininases. The two main
kininases are kininase II, which has been found to be identical with ACE, and neutral
endopeptidase.
A decreased activity of the renal kallikrein-kinin system has been found in essential hypertension
and in rat models of genetic hypertension (for review, see Majima and Katori 1995). Thus, the renal
kallikrein-kinin system may have a crucial role in the development of hypertension.
The cardiovascular effects of the kallikrein-kinin system have been studied, e.g., by using B2
receptor antagonist icatibant (HOE 140). Inhibition of bradykinin breakdown by ACE inhibitors
leads to increased B2 receptor activation. Icatibant has been reported to partly antagonise the
antihypertensive effects of ACE inhibitors in experimental animals (Bao et al. 1992; O'Sullivan and
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Harrap 1995). Therefore, increased availability of bradykinin seems to be responsible for some of
the beneficial effects of ACE inhibitors.
2.3.1.3. Cyclosporine A and renin-angiotensin system
Several lines of evidence suggest an involvement of RAS in CsA toxicity. In rats, activation of RAS
by CsA is a consistent finding. An increase in PRA has been demonstrated in CsA-treated rats on
sodium-depletion (Burdmann et al. 1995), normal-sodium (Abassi et al. 1996) or high-sodium diets
(Mervaala et al. 1997). Increased PRA by CsA has been related to increased renin expression in the
juxtaglomerular apparatus (Young et al. 1995a). In vitro, CsA stimulated renin production and
release from juxtaglomerular cells (Kurtz et al. 1988). The mechanism for this direct effect is
obscure, but it is proposed to be linked to cyclophilin binding (Kurtz et al. 1988; Lee 1997).
Furthermore, CsA increased local expression of angiotensin II in the outer medulla and medullary
rays (Ramirez et al. 2000).
CsA has been reported to elevate PRA in cardiac and liver transplant patients (Julien et al. 1993)
and plasma angiotensin II levels in patients with psoriasis (Edwards et al. 1994). Data of the effects
of CsA on RAS in man are, however, to some extent contradictory; normal or even low PRA have
been reported (Bantle et al. 1987; Myers et al. 1988; Mason et al. 1991). There is evidence of CsA-
induced juxtaglomerular hyperplasia related to increased total renin content and impaired intrarenal
conversion of inactive prorenin to active renin (Bantle et al. 1987; Myers et al. 1988; Mason et al.
1991). CsA may raise angiotensin II levels by increasing the activity of ACE which has been
detected in serum of patients (Letizia et al. 1995) as well as in serum and in lung tissue of rats
(Erman et al. 1990). Therefore, the lack of increase in PRA in some clinical studies does not
exclude activation of RAS. It has been suggested that CsA causes activation of tissue RAS, which is
not always seen as a change in PRA (Mason et al. 1991; Young et al. 1995a; Ramirez et al. 2000).
Chronic administration of angiotensin II in rats produces renal injury resembling that observed in
CsA nephropathy in man (Giachelli et al. 1994; Noble and Border 1997). Both angiotensin II and
CsA cause an overexpression of TGF-β1, a growth factor which has been implicated in the
pathophysiology of many fibrotic diseases of the kidney and other organs (Pichler et al. 1995; Noble
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and Border 1997). In addition, both angiotensin II (Giachelli et al. 1994) and CsA (Pichler et al.
1995) increase tubulointerstitial expression of osteopontin, an adhesion molecule associated with
renal fibrosis. Thus, activation of RAS by CsA seems to be at least partly responsible for interstitial
fibrosis through stimulation of TGF-β1 and osteopontin expression.
Antagonism of RAS by ACE inhibitors and AT1 receptor antagonists lowers blood pressure in CsA
patients (Mourad et al. 1993; Sennesael et al. 1995; Hannedouche et al. 1996; Del Castillo et al.
1998; Taler et al. 1999). Clinical studies suggest that the CsA-induced hypertension can be treated
with several classes of antihypertensive drugs including ACE inhibitors, AT1 receptor antagonists,
calcium antagonists and adrenergic β-receptor antagonists. However, some studies suggest that
ACE inhibitors alone have limited antihypertensive effects directly after transplantation (Textor et
al. 1988; Taler et al. 1999).
In normotensive rats during sodium deprivation, antagonism of RAS with enalapril and losartan
prevented CsA-induced morphological nephrotoxicity without affecting blood pressure (Burdman et
al. 1995; Pichler et al. 1995). In the same animal model, arteriolopathy and interstitial fibrosis were
diminished by RAS inhibition with enalapril and losartan, but not by some other classes of
antihypertensive drugs such as calcium antagonist nilvadipine, vasodilatator dihydralazine or
diuretic furosemide (Shihab et al. 1997), while blood pressure remained unaffected by any of the
treatments. AT1 receptor antagonist losartan reduced CsA-induced interstitial fibrosis in sodium-
deprived rats concomitantly with decreasing renal TGF-β1 and osteopontin expression (Pichler et al.
1995). Additionally, in a one-year study of normotensive rats on normal-sodium diet, CsA caused
tubulointerstitial fibrosis without affecting blood pressure (Lafayette et al. 1993). Both concomitant
enalapril and a combination of potassium channel opener minoxidil, monoamine transporter
inhibitor reserpine and diuretic hydrochlorothiazide lowered blood pressure, but only enalapril
prevented morphological damage of the kidneys. These studies suggest that angiotensin II has a
specific role in the development of CsA-induced morphological renal damage. The effect of
angiotensin II seems to be, at least partly, independent of blood pressure changes.
The effects of drugs suppressing RAS on CsA-induced renal dysfunction are unclear. Theoretically,
it is possible that suppression of RAS might be harmful. CsA reduces the glomerular filtration rate
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and renal blood flow by causing vasoconstriction of the glomerular afferent arterioles (Murray et al.
1985; Myers et al. 1988). When renal blood flow is substantially reduced, angiotensin II contributes
to the maintenance of the glomerular filtration rate by constricting the efferent glomerular arterioles
(Hall et al. 1999). Under such conditions, dilation of the efferent arterioles by drugs suppressing
RAS may potentiate the reduction in the glomerular filtration rate.
In sodium-depleted normotensive rats, enalapril and losartan prevented CsA-induced renal
morphological changes but not the decrease in glomerular filtration rate (Burdmann et al. 1995; Kon
et al. 1995; Pichler et al. 1995). In this rat model, it seems that renal dysfunction is related to
activation of the endothelin system, whereas morphological damage is related to activation of RAS
(Burdmann et al. 1995; Kon et al. 1995; Pichler et al. 1995). There are case reports in which ACE
inhibitors have worsened the renal function of CsA-treated kidney transplant patients (Garcia et al.
1994). In most human studies, however, ACE inhibitors have lowered blood pressure, but have not
affected renal function in CsA-treated renal-allograft patients (Sennesael et al. 1995; Hausberg et al.
1999). Furthermore, enalapril prevented the CsA-induced decline in glomerular filtration rate in
diabetic patients (Hannedouche et al. 1996). Likewise, in CsA-treated normotensive rats on normal-
sodium diet, ACE inhibitor captopril and AT1 receptor antagonist saralasin increased glomerular
filtration rate and renal blood flow (Kaskel et al. 1987). Taken together, it seems that suppression of
RAS is not harmful for renal function of all CsA-treated patients and may in fact improve it in some
cases. However, a subgroup of patients may exist, for example, kidney transplant patients, who are
more susceptible than others to renal dysfunction due to cotreatment of CsA and a drug suppressing
the activity of RAS.
CsA may cause cardiovascular effects via RAS by mechanisms which are independent of the rate of
angiotensin II formation. Long-term treatment with CsA upregulated AT1 receptors in rat vascular
and renal tissues (Iwai et al. 1993; Regitz-Zagrosek et al. 1995). Similarly, CsA-incubation
upregulated AT1 receptors in human vascular cells and potentiated the rise in intracellular calcium
concentration in response to angiotensin II (Avdonin et al. 1999). According to culture studies of rat
vascular smooth muscle cells, it seems that CsA increases the intracellular calcium concentration by
several mechanisms: CsA stimulated transmembrane calcium influx (Lo Russo et al. 1996; Meyer-
Lehnert et al. 1997), and augmented angiotensin II-stimulated calcium influx and efflux
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(Pfeilschifter and Ruegg 1987). There is evidence that CsA may also mobilise calcium from the
intracellular stores by activating the phosphoinositol pathway (Lo Russo et al. 1997). In addition,
calcium may be released from intracellular stores by CsA by a mechanism which does not involve
activation of the phosphoinositol pathway, but is due to a direct effect on intracellular calcium
stores (Gordjani et al. 2000). In accordance with the above-mentioned mechanisms, repeated
administration of CsA has been reported to increase the vasoconstrictive effect of angiotensin II
(Auch-Schwelk et al. 1993; Takeda et al. 1995).
Very recently, a different view about the interaction of CsA and RAS has been presented. CsA
antagonised the harmful effects of RAS overexpression on end-organ damage in double transgenic
rats harbouring human renin and angiotensinogen genes (Mervaala et al. 2000). The protection was
due to anti-inflammatory properties of CsA by inhibition of interleukin-6 and inducible nitric oxide
synthase (iNOS) expression. It seems that CsA may not only cause renal and cardiovascular toxicity
via induction of RAS, but can also antagonise inflammatory responses to various stimuli, including
angiotensin II.
2.3.1.4. Cyclosporine A and renal kallikrein-kinin system
Only a few reports exist about the role of the renal kallikrein-kinin system in CsA toxicity. In
normotensive rats, CsA at 20 mg/kg/day for three days decreased renal kallikrein and bradykinin B2
receptor levels (Bompart et al. 1996). In another study, CsA-administration at 25 mg/kg/day for 28
days increased renal kallikrein and bradykinin B2 receptor levels (Wang et al. 1997). This was
proposed to occur as compensation for drug-induced vasoconstriction and hypertension. In patients
with psoriasis, a reduced urinary kallikrein excretion was detected after six-month treatment with
CsA (Raman et al. 1998). No studies of CsA with icatibant have been reported. Thus, the renal
kallikrein-kinin system may have a role in CsA toxicity, but requires further studies before any
conclusions can be drawn.
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2.3.2. Endothelium, nitric oxide and oxidative stress
2.3.2.1. Role of endothelium in control of cardiovascular functions
The endothelial cell layer participates in the control of vascular tone and blood pressure by
producing relaxing and contracting factors, thus modulating the tone of the underlying smooth
muscle. Dysfunction of vascular endothelium, characterised by a decrease in endothelium-
dependent relaxation, is shown in human essential hypertension and in various models of
experimental hypertension (for review, see McIntyre et al. 1999). In SHR, the dysfunction occurs
already before the onset of hypertension (Jameson et al. 1993). Impaired endothelial dysfunction is
reported in the normotensive offspring of hypertensive patients (Taddei et al. 1996). Endothelial
dysfunction can be improved by antihypertensive therapy in rats and in humans (for review, see
Vapaatalo et al. 2000).
Nitric oxide (NO) is a lipophilic gas which is formed enzymatically from its precursor L-arginine by
three isoforms of NO synthase (NOS), endothelial eNOS, neuronal nNOS and inducible iNOS (for
review, see Stuehr 1999). NO diffuses to the vascular smooth muscle cells and activates guanylate
cyclase, which leads to the increased production of cyclic guanosine 3',5'-monophosphate (cGMP)
(Figure 4). cGMP-dependent kinase regulates several pathways involved in calcium homeostasis.
NO also hyperpolarises vascular smooth muscle cells via cGMP-dependent pathway as well as
direct effects on calcium-dependent potassium channels and Na+-K+ ATPase (for review, see Busse
and Fleming 1995). In vivo, NO is destroyed mainly by superoxide anion (for review, see Stuehr
1999). Because of its short half-life (0.1 seconds in vivo), NO acts primarily as a paracrine hormone
(Loscalzo and Welch 1995). Activity of NOS isoforms is regulated in different ways. Constitutive
NO production by eNOS is controlled by intracellular calcium concentration following physical
(shear stress) or chemical stimuli of various receptors for endogenous substances. iNOS is
controlled mainly by inflammatory cytokines such as interleukin-1 and tumor necrosis factor-α (Rao
2000). High amounts of NO are released by iNOS in response to inflammatory stimuli from a
variety of cell types (Rao 2000).
26
M
B2 L-citrulline
L-arginine
Acetyl-
choline
Shear
stress
Brady-
kinin
cGMP
GTP
NO. NO.
Endothelial cell Smooth muscle cell
eNOSCa2+↑
Vasodilation
Platelet aggregation ↓
Smooth muscle growth ↓
Neutrophil adhesion ↓
Vascular lumen
GC
ONOO-
.OH
NO. inactivation
Oxidative stress
Figure 4. L-arginine−nitric oxide system. B2, bradykinin B2 receptor; cGMP, cyclic guanosine 3',5'-
monophosphate; eNOS, endothelial nitric oxide synthase; GC, guanylate cyclase; GTP, guanosine
5'-triphosphate; M, muscarinic receptor; NO, nitric oxide; .OH, hydroxyl radical; ONOO-,
peroxynitrite.
In addition to NO, prostanoids have a major role in the control of vascular function. Prostanoids,
including PGI2 and PGE2, are produced from arachidonic acid, which is liberated from the cell
membrane phospholipids by phospholipase A2. The effects of PGI2, the most important vasodilating
prostaglandin, are mediated by membrane receptors on the smooth muscle cells. Stimulation of
these receptors activates adenylate cyclase, which leads to increased intracellular concentrations of
cAMP, and further to hyperpolarisation of the cell membrane, reduction of intracellular calcium
concentration and decreased sensitivity of contractile proteins to calcium (for review, see Cohen and
Vanhoutte 1995).
Recent evidence suggests that a factor called endothelium-derived hyperpolarising factor contributes
to endothelium-mediated vasodilation by increasing the conductance of smooth muscle cells to
potassium ions (for review, see Cohen and Vanhoutte 1995). The release of endothelium-derived
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hyperpolarising factor is believed to be initiated by an increase in free calcium concentration in the
endothelial cell. The chemical structure of the substance or possibly of several different substances
is not known. Endothelium-derived hyperpolarisation may, at least partly, account for nonprostanoid
products of arachidonic acid metabolism (Cohen and Vanhoutte 1995; Fisslthaler et al. 2000).
The endothelium is also a source of contracting factors. A gene codes for three isoforms of
endothelins (1, 2 and 3), which are generated in two steps from preproendothelins. First, neutral
endopeptidase forms the intermediate product proendothelins, which are further activated by
endothelin converting enzyme (Benigni and Remuzzi 1999). They act via two receptor subtypes (A
and B). Other important endothelium-derived contractile factors include cyclooxygenase product
thromboxane A2 and prostaglandin endoperoxide intermediates prostaglandin G2 and H2 (Cohen
1995). All of these substances contract smooth muscle cells via thromboxane A2 receptors (Cohen
1995).
2.3.2.2. Oxidative stress
Endothelial cells are both significant sources and targets of reactive oxygen products, including
superoxide anion, hydroxyl radical, hydrogen peroxide and peroxynitrite (for review, see McIntyre
et al. 1999). These products can inhibit vascular relaxation by neutralising the effects of NO, but
they may also have direct vasoconstrictive properties (Cosentino et al. 1994). The main sources of
reactive oxygen products are respiratory chain enzymes in the mitochondria, such as aldehyde
oxidase, dihydroorotic dehydrogenases, flavin dehydrogenases, peroxidases, cyclooxygenase, NOS,
and auto-oxidation of a large group of compounds including catecholamines, flavins and ferredoxin.
Many enzymes, including superoxide dismutases, can inactivate reactive oxygen products (McIntyre
et al. 1999).
Increased superoxide production has been shown in endothelial cells from stroke-prone SHR
(Grunfeld et al. 1995). In addition, aortic rings from SHR are more sensitive to contractions induced
by oxygen-derived free radicals than those from Wistar-Kyoto rats (Auch-Schwelk et al. 1989).
Increased vascular oxidative stress has also been demonstrated in SHR in vivo (Suzuki et al. 1995;
1998). These studies suggest that genetic hypertension is associated with increased oxidative stress.
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Endothelial dysfunction was earlier thought to be attributed mostly to decreased production of NO
either due to decreased activity of eNOS or to a deficiency in the availability of L-arginine (Palmer
et al. 1988). L-arginine causes vasodilation and lowering of blood pressure in experimental animals
and in man (for review, see Li and Förstermann 2000). However, recent evidence suggests that
impaired endothelium-dependent relaxation is associated with increased rather than decreased
expression of eNOS in vasculature (Boulomie et al. 1997). eNOS can also catalyse superoxide
formation in a reaction which is primarily regulated by cofactor tetrahydrobiopterin rather than
L-arginine (Vasquez-Vivar et al. 1998). Thus, it seems that for normal endothelial function the
balance between NO and superoxide anion is more important than the absolute levels of either alone
(McIntyre et al. 1999).
2.3.2.3. Effects of cyclosporine A on vascular function
Repeated in vivo administration of fairly high doses of CsA has been found to impair endothelium-
dependent relaxation to acetylcholine in the rat aorta (Mikkelsen et al. 1992; Auch-Schwelk et al.
1994; Verbeke et al. 1995; Kim et al. 1996), in femoral arteries (Gallego et al. 1994) and in
mesenteric arteries (Rego et al. 1990). In CsA-treated transplant recipients, renal vasodilatory
response to L-arginine infusion was reduced with a concomitant lowering of urinary nitrate
excretion (Gaston et al. 1995). Likewise, CsA treatment in rheumatoid arthritis patients attenuated
the vasodilatory responses to isoprenalin and PGE2 (Stein et al. 1995). CsA inhibited endothelium-
dependent relaxation in vivo in liver transplant recipients (Albillos et al. 1998) and in vitro in
subcutaneous resistance vessels obtained from normal subjects undergoing routine surgery
(Richards et al. 1990).
Some evidence suggests that endothelial dysfunction is due to direct toxicity of CsA on endothelial
cells. CsA-induced dysfunction was associated with concomitant endothelial damage in rats (Kim et
al. 1996). In addition, incubation of bovine aortic endothelial cells with CsA at a therapeutically
relevant concentration of 1 µM resulted in cell lysis (Zoja et al. 1986).
CsA has been reported to impair endothelium-independent relaxations in rats (Gallego et al. 1993;
Kim et al. 1996), but endothelium-independent relaxations have also been reported to remain
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unaltered (Oriji and Keiser 1998). Response to nitroglycerin was unchanged by CsA in patients
(Stein et al. 1995).
CsA contracted renal arteries and arterioles of rats in vitro (Lanese et al. 1994; Epstein et al. 1998).
Repeated administration of CsA has been reported to increase (Rego et al. 1990), decrease (Roullet
et al. 1995) or have no effect (Ressureicao et al. 1995) on contractile responses in mesenteric
arteries of rats. Likewise, repeated administration of CsA has been reported to sensitise renal
arteries of rats to noradrenaline (Mikkelsen et al. 1992), but this has not been confirmed by all
studies (Diederich et al. 1992). In patients, contractile responses to noradrenaline remained
unaltered by CsA (Stein et al. 1995).
Taken together, CsA causes vascular dysfunction in vivo which is characterised by decreased
endothelial relaxations in man and in rats. In addition, CsA increases vascular contractility in vitro.
2.3.2.4. Effects of cyclosporine A on nitric oxide synthase
According to previous studies, CsA seems to have different effects on iNOS and eNOS expression
(Table 2 and 3). Increased NO synthesis and eNOS mRNA and protein levels have been reported in
endothelial cells exposed to CsA in vitro (Lopez-Ongil et al. 1996). The induction of eNOS seems
to be due to transcriptional induction of the eNOS gene (Navarro-Antolin et al. 2000). CsA also
caused monocyte eNOS upregulation in renal transplant patients (Calo et al. 1998) and eNOS
overexpression in the rat kidneys (Amore et al. 1995) and in the renal cortex of uninephroctomised
rats (Bobadilla et al. 1998). In addition, acute infusion of CsA into human forearm vessels increased
NO activity in vivo (Stroes et al. 1997). However, long-term treatment with CsA did not affect renal
or vascular eNOS expression in rats (Vaziri et al. 1998), suggesting that induction of eNOS by CsA
is unclear in vivo.
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CsA inhibited transcription of iNOS in murine macrophage and vascular smooth muscle cells
(Dusting et al. 1999). In addition, depressed renal iNOS expression has been reported in vivo in rats
after CsA treatment (Bobadilla et al. 1998; Vaziri et al. 1998; Mervaala et al. 2000). CsA also
impaired iNOS in rat aortic smooth muscle cells (Marumo et al. 1995) and inhibited NO production
in cultured macrophages (Conde et al. 1995).
Little is known about the effects of CsA on nNOS. Long-term CsA administration has been reported
to decrease nNOS expression in uninephroctomised rats (Bobadilla et al. 1998).
L-arginine has been shown to have a beneficial effect on CsA-induced endothelial dysfunction
(Gallego et al. 1993; Prieto et al. 1997; Oriji and Keiser 1998) and on renal haemodynamics in
CsA-treated rats (De Nicola et al. 1993). Short-term treatment with L-arginine also reversed CsA-
induced hypertension (Oriji and Keiser 1998).
2.3.2.5. Effects of CsA on oxidative stress
Several lines of evidence suggest that CsA-induced renal and cardiovascular toxicity may be due to
oxidative stress. CsA increases hypoxia and free radical production in the rat kidney (Zhong et al.
1998). Antioxidants, such as α-tocopherol, ascorbate, lazaroids and superoxide dismutase/catalase,
have been shown to diminish CsA-induced renal toxicity (Wang and Salahudeen 1994; Wolf et al.
1994).
The mechanisms and the role of oxidative stress in CsA toxicity are unknown. Free radicals may be
derived directly from CsA or its metabolites (for review, see Buetler et al. 2000). Reperfusion
subsequent to CsA-induced renal vasoconstriction and hypoxia may also increase formation of free
radicals. One possible mechanism of CsA-evoked oxidative stress is eNOS hyperactivity.
Chronically administered CsA increased eNOS activity in the rat kidney parallel with decreased
renal function (Amore et al. 1995). The functional nephrotoxicity by CsA was prevented by
L-arginine (Amore et al. 1995). The protective effect of L-arginine was reversed by NOS inhibitor,
suggesting that NO was crucial in the effect of L-arginine (Amore et al. 1995). While the
intracellular L-arginine is sufficient for basal NO production in endothelial cells (Arnal et al. 1995),
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the substrate supply may be inadequate for the escalated demands of activated NOS. During
insufficient L-arginine supply, the increase in NOS activity would not correspond to increased
production of NO. Instead, NOS may generate reactive superoxide anion and other oxygen radicals
(Stamler et al. 1992). L-arginine treatment might prevent this by shifting NOS activity toward NO
generation and reduced oxidant injury.
Some mechanisms of CsA-induced radical oxygen species generation besides eNOS hyperactivity
have been suggested. These include alterations in calcium homeostasis, leading to vasoconstriction
and CsA metabolism by cytochrome P450 system (CYP450), more specifically, the CYP450 3A
isoenzyme (Ahmed et al. 1995; Buetler et al. 2000).
2.3.3. Renal sodium handling
2.3.3.1. Role of renal sodium handling in blood pressure control
Kidneys play a pivotal role in the regulation of sodium balance. Several modulatory factors can
control sodium excretion to a certain degree. These include RAS, aldosterone, the renal renal
kallikrein-kinin system, dietary intake of potassium, calcium and magnesium, natriuretic peptides
and endothelium-derived factors. According to the pressure-natriuresis theory presented by Guyton
et al. (1972), an increase in dietary sodium beyond the control of these regulatory factors causes a
rise in blood pressure to get rid of excess sodium. High sodium intake is one of the risk factors for
development of hypertension in rats and in humans (Mervaala et al. 1992; Dyer et al. 1994).
2.3.3.2. Effects of cyclosporine A on renal sodium handling
In rats, short-term CsA administration reduced urinary excretion of sodium (Ryffel et al. 1986;
Kaskel et al. 1987). Vasoconstriction of renal arterioles causes a reduction in perfusion pressure that
may cause sodium retention and, therefore, a rise in blood pressure. In SHR, CsA caused a
pronounced rise in blood pressure and renal dysfunction during high intake of sodium (Mervaala et
al. 1997). In contrast, during normal-sodium diet, the blood pressure increasing effect of CsA was
only moderate and no effect on renal function was observed. Evidence also exists for disturbances
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in renal sodium handling playing a role in CsA-induced hypertension in patients. Sodium restriction
has been shown to lower blood pressure in hypertensive transplant recipients treated with CsA, but
not in hypertensive transplant recipients treated with azathioprine and glucocorticoids (Curtis et al.
1988; Curtis 1994). These findings together suggest that high intake of sodium is a risk factor for
CsA-induced hypertension and renal toxicity.
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3. AIMS OF THE STUDY
The exact mechanisms of cyclosporine A-induced hypertension and nephrotoxicity remain
unknown. The renin-angiotensin system is proposed to play an important role in cyclosporine A
toxicity, although some studies contradict this. The present study aimed at relating possible
alterations in this system to functional and morphological changes in the vasculature and the kidney,
also taking into consideration the kallikrein-kinin system, the L-arginine−nitric oxide pathway and
oxidative stress. Spontaneously hypertensive rats on high-sodium diet were used as a model of
cyclosporine A-induced hypertension and nephrotoxicity in patients.
The specific aims were to:
1. examine the long-term effects of cyclosporine A on blood pressure and on end-organ functions
and morphology.
2. relate cyclosporine A-induced changes in vascular function with morphology.
3. investigate the role of the renin-angiotensin system and the renal kallikrein-kinin system in
cyclosporine A toxicity.
4. evaluate the importance of the L-arginine−nitric oxide pathway and oxidative stress in
cyclosporine A toxicity.
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4. MATERIALS AND METHODS
4.1. Experimental animals
Male SHR (Harlan Sprague Dawley, Indianapolis, IN, USA) aged 7−9 weeks at beginning of the
experiment were used. The rats were housed in a standard animal laboratory room (temperature
22−24°C, a 12-hour light-dark cycle). The rats had free access to tap water and feed, and were
weighed daily during the experiment. All rats were placed on high-sodium diets during the six-week
treatment (sodium 2.6%, magnesium 0.2%, potassium 0.8%, calcium 1.0%, phosphorous 0.75% of
the dry weight of the feed; R36, Finnewos Aqua, Helsinki, Finland). The food was prepared by
adding sodium chloride to the commercially available rat feed.
The protocols of the studies were approved by the Animal Experimentation Committee of the
Institute of Biomedicine, University of Helsinki, Finland.
4.2. Drug treatments
CsA was administered subcutaneously at a dose of 5 mg/kg/day. This dose has been shown to result
in CsA plasma concentrations similar to those measured in CsA-treated patients (Mervaala et al.
1997). Control rats received the same volume (1 ml/kg) of the vehicle. Enalapril and valsartan were
mixed in the food to produce the planned daily doses. The dose of enalapril (30 mg/kg/day) was
chosen to be comparable with previous studies to reduce blood pressure in SHR (Nunez et al.
1997). The higher dose of valsartan (30 mg/kg/day) has been reported to produce a marked
antihypertensive effect, whereas the lower dose (3 mg/kg/day) caused a slight antihypertensive
effect during long-term administration (Yamamoto et al. 1997). Icatibant was administered by a
subcutaneous osmotic minipump for two weeks. The dose of icatibant (500 µg/kg/day) has been
shown to inhibit the cardiovascular effects of bradykinin in rats (Bao et al. 1992; O'Sullivan and
Harrap 1995). L-arginine (1.7 g/kg/day) in drinking water has been shown to antagonise the effects
of CsA in Sprague Dawley rats during sodium deprivation (Andoh et al. 1997). The design of the
individual studies is presented in Table 4.
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4.3. Measurement of systolic blood pressure and heart rate
Systolic blood pressure and heart rate were measured every second week (I, II) or every week (IV)
using a tail cuff blood pressure analyser (Apollo-2AB Blood Pressure Analyser, Model 179-2AB,
IITC Life Science, Woodland Hills, CA, USA). This method has been reported to show good
correlations with parallel recordings from intra-arterial catheters in rats (Bunag and Butterfield
1982).
4.4. Collection of samples
During the last week of the experiment, the rats were housed individually in metabolic cages for
24−48 hours. The consumption of food and tap water was measured by weighing the feed and the
water bottles, respectively. Urine was collected for biochemical determinations.
At the end of the experiments, the animals were made unconscious with CO2/O2 70/30% (AGA,
Riihimäki, Finland) and decapitated 24 hours after the last CsA administration. Blood samples were
taken into chilled tubes with or without EDTA (4.5 mM). The heart was excised, the great vessels,
atria and free wall of the right ventricle were dissected and the left ventricular mass was weighed.
The kidneys were washed with ice-cold saline and weighed.
4.5. Arterial responses
A 2 to 3-mm-long section of the right renal artery and a 3-mm-long section of the mesenteric artery
5 mm distally from the mesenteric artery-aorta junction were cut (III, IV). The rings were placed
between stainless steel hooks, mounted in an organ bath chamber in Krebs-Ringer buffer and
equilibrated for 30 min at 37°C, with a resting tension of 0.2 g for renal and 1.0 g for mesenteric
arteries. The isometric force of contraction was registered with a polygraph (FTO3 transducer,
Model 7P122E Polygraph; Grass Instrument, Quincy, MA, USA).
Cumulative concentration-response curves for noradrenaline (III, IV) and potassium chloride (IV)
and the response to a single administration of angiotensin II (III) were determined. Angiotensin II
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was administered only once to avoid tachyphylaxis (Khairallah et al. 1966). Cumulative relaxation
responses to acetylcholine and sodium nitroprusside were examined after precontraction with
noradrenaline (III, IV).
4.6. Histology
4.6.1. Sample preparation
Cross-sections of the kidney, a section of the mesenteric arterial trunk with the first- and second-
order branches and the arterial bed, a section of the renal artery and coronal sections of the left
ventricle were cut. The samples were fixed for 24−48 hours with 10% formaline and then
dehydrated and embedded in paraffin. Thereafter, the samples were deparaffinised, hydrated and
stained with Masson’s trichrome. All slides were evaluated by light microscopy without knowledge
of sample identity.
4.6.2. Kidneys
Interstitial, tubular and glomerular changes were looked for (I, II, IV). In study II, the renal slides
were scored according to arterioglomerular changes using the method described by Pere et al.
(1998): 100 consecutive glomeruli and their afferent arterioli from each kidney slide were assigned
for severity of changes using scores from 0 to 3 (0=normal, 1=slight, 2=severe, 3=necrosis).
Thereafter, a glomerular damage index was calculated by assessing 100 consecutive
arterioglomerular units in each kidney and counting the number of affected glomeruli in each score
group.
4.6.3. Arteries
Periadventitial, adventitial, medial and intimal changes were registered in renal and mesenteric
vessels. Vessels from mesenteric beds were recorded by morphometric analysis with an image
operating system (AnalySIS, 3.0 Soft Imaging System GmbH, Munich, Germany). The corrected
area of the media was determined using the cross-sectional area of the media and a correction for
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eccentricity of the sections (Lee et al. 1983). The corrected medial area was expressed as a ratio to
the mean diameter of the whole vessel to exclude the effect of vessel size on the measured area. The
mean axis was determined as a mean of the longest and shortest axes seen in the picture. On the
basis of vascular diameter, the arteries were divided into two categories: less than 100 µm
(resistance arteries and arterioles) and 100−400 µm (the first- and second-order branches from the
superior mesenteric artery).
4.6.4. Heart
The effect of CsA and enalapril on vascular and myocardial changes of the heart were investigated
(I).
4.7. Biochemical determinations
4.7.1. Urinary electrolytes
In study I, urinary sodium, potassium, magnesium, calcium and phosphorous concentrations were
determined using a Baird PS-4 inductively coupled plasma emission spectrometer (Baird Co,
Bedford, MA, USA). Otherwise, urinary magnesium concentration was measured using an atom
absorption spectrophotometer (II) (BM/Hitachi 917 analyser, Boehringer Mannheim,
Germany/Hitachi Ltd, Tokyo, Japan). Urinary sodium and potassium were determined by flame
photometer using an ion selective electrode-compensator (II, IV) (human serum pool, IL Model 943,
Instrumentarium Laboratory, Milan, Italy).
4.7.2. Plasma renin activity, urinary kallikrein and protein, serum and urinary creatinine
Plasma renin activity (PRA) was determined by a radioimmunoassay of angiotensin I (Medix
Angiotensin I test®, Medix Biochemica, Kauniainen, Finland). Total protein concentration of urine
was determined by the method of Lowry et al. (1951) after precipitation of proteins with 10%
trichloroacetic acid. Urinary and serum creatinine were analysed by the Jaffe method (Bartels et al.
1972) (BM/Hitachi 917 analyser) without deproteinisation. Creatinine clearance as an index of
glomerular filtration rate was calculated by dividing the average 24-hour urinary creatinine
41
excretion rate by serum concentration of creatinine. Urinary kallikrein activity was measured by
amidolytic assay using a chromogenic tripeptide substrate H-D-valyl-L-leucyl-L-arginine-p-
nitroaniline dihydrochloride (Amundsen et al. 1979).
4.7.3. Urinary cyclic guanosine 3',5'-monophosphate, tissue nitric oxide synthase expression, urinary
8-isoprostaglandin F2α, plasma total radical trapping parameter and urate
Urinary cGMP was measured by radioimmunoassay (Axelsson et al. 1988). eNOS and iNOS
expression in heart, aorta, kidney medulla and kidney cortex were analysed by Western blotting
using primary antibody mouse monoclonal anti-eNOS IgG1 (1:2500, Transduction Laboratories,
Lexington, KY, USA) or rabbit polyclonal anti-iNOS IgG (1:6000, Santa Cruz Biotechnology,
Santa Cruz, CA, USA).
Urinary 8-isoprostaglandin F2α was analysed by radioimmunoassay. Nonlabeled 8-isoprostaglandin
F2α was obtained from Cayman Chemical Co (Ann Arbor, MI, USA). 8-[125I] isoprostaglandin F2α-
tyrosine methyl ester and 8-isoprostaglandin F2α antibody were supplied by Dr. István Mucha,
Institute of Isotopes Co, Budapest, Hungary. Total radical trapping parameter (TRAP) was
measured by a chemiluminescence method (Metsä-Ketelä 1991) using 2,2-azo-bis(2-aminopropane)
hydrochloride (ABAP; Polysciences, Warrington, PA, USA) as peroxyl radical producer. A water-
soluble tocopherol, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; Hoffmann-
La Roche Ltd, Basel, Switzerland) was used as a standard to calculate TRAP values (Wayner et al.
1987). Urate concentrations in plasma were measured colorimetrically (Sigma Chemical Co, St.
Louis, MO, USA).
The urinary excretions and creatinine clearance were expressed per 100 g of body weight in studies
II and IV.
4.8. Cell cultures
Smooth muscle cells were taken for cell culture from the aorta of the SHR on high-sodium diet
which had received CsA or vehicle for six weeks (n=4 per group). The procedure for obtaining the
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vascular smooth muscle cells for culture was slightly modified from the explant technique (Pang
and Venance 1992). The viability of the cells was tested in a culture for 7 days. Cells from the third
passage were used for the experiment. The cells from the control and CsA groups were plated in a
concentration of 106 per petri dish. After seven days, the cells were detached from the dishes and
counted.
4.9. Compounds
The following compounds were used: Cyclosporine A (Sandimmun® 50 mg/ml infusion
concentrate, Novartis Ltd, Basel, Switzerland), valsartan (Novartis Ltd, Basel, Switzerland),
enalapril maleate (Leiras Ltd, Turku, Finland), icatibant (d-Arg[Hyp3,Thi5,D-Tic7,Oic8]-bradykinin,
Hoechst AG, Frankfurt am Main, Germany), a lipid solution (Intralipid®, Kabi Pharmacia,
Stockholm, Sweden), L-arginine, acetylcholine chloride, angiotensin II, noradrenaline bitartrate
(Sigma Chemical Co), sodium nitroprusside dihydrate (F. Hoffmann-La Roche AG, Basel,
Switzerland) and sodium pentobarbital (The University Pharmacy, Helsinki, Finland). The stock
solutions of the compounds used in in vitro studies were dissolved in distilled water. All solutions
were freshly prepared before use and protected from light.
4.10. Statistical analysis
The results are expressed as means ± S.E.M. The results for cumulative arterial responses and
systolic blood pressure were analysed using two-way analysis of variance (ANOVA) with repeated
measures for overall treatment effect. Other data were analysed by one-way ANOVA. Tukey’s test
(II, III, IV) or Duncan's test (I) were used for pairwise comparisons between treatment groups. The
results for PRA were not normally distributed and were, therefore, analysed by the Kruskal-Wallis
ANOVA and the Mann-Whitney U-test (II). Bonferroni correction (p’=p∗k) was applied to the
resultant P values to allow pairwise comparisons of multiple groups (Ludbrook 1994). Data for the
experiment with icatibant were analysed by the Student's t-test. P<0.05 was considered significant.
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5. RESULTS
5.1. Blood pressure, heart rate and left ventricle weight
The effect of six-week CsA treatment on blood pressure, heart rate and the left ventricle weight-to-
body weight ratio was evaluated in SHR during the developmental phase of hypertension. Systolic
blood pressure was 37−55 mmHg higher in CsA-treated SHR than in control SHR on high-sodium
diet (I, II, IV) (Table 5). Concomitant enalapril at 30 mg/kg/day (I and II) and valsartan at 3 and 30
mg/kg/day dose-dependently (II) antagonised the hypertensive effect of CsA. Icatibant at 500
µg/kg/day had no effect on blood pressure during CsA and enalapril administration (II). L-arginine
at 1.7 g/kg/day did not significantly influence CsA-induced hypertension (IV).
CsA increased heart rate during the six-week treatment (I, II, IV) (Table 5). Concomitant enalapril,
valsartan, icatibant or arginine treatment had no effect on heart rate as compared with CsA alone.
The cardiac effects of CsA varied: CsA increased the left ventricle weight-to-body weight ratio in
study IV and tended to do so in study II (P=0.098), whereas in study I the left ventricle weight-to-
body weight ratio was unaffected by CsA (Table 5). Concomitant enalapril and both doses of
valsartan lowered this ratio as compared with CsA alone or with the control group (I, II). Icatibant
had no effect on the left ventricle weight-to-body weight ratio during CsA and enalapril
administration (II). The left ventricle weight-to-body weight ratio remained unaltered with
concomitant L-arginine (IV).
5.2. Body weight gain, food and water consumption, urinary volume and electrolyte excretion
To find out whether CsA or other drugs affected normal well-being of the animals, body weight
gain and food and water consumption were studied. CsA reduced body weight gain 7−15% as
compared with control rats in each study. Concomitant enalapril, valsartan, icatibant or L-arginine
had no effect on body weight gain when compared with CsA alone.
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No significant differences in food intake between the experimental groups were detected at the end
of the experimental period (I, II, IV). Increased water intake and urinary volume by CsA was
observed in studies I and IV, whereas enalapril normalised these parameters. In other studies, no
differences were present between groups in the intake of water (II, IV). Enalapril and the higher
dose of valsartan, but no other treatment, lowered urinary volume below that of control rats (II).
A lowered (I, II) or similar (IV) sodium excretion was detected of the CsA group compared with the
control group at the end of the study. Potassium excretion was detected to be either lowered (I, II) or
unaffected (IV) by CsA. CsA increased (I) or had no effect (II) on magnesium excretion. Any
concomitant treatment did not influence sodium, potassium or magnesium excretions during CsA
treatment (I, II, IV). CsA increased calcium and phosphorous excretion, whereas enalapril
attenuated this effect (I).
5.3. Renal function
CsA caused renal dysfunction with marked proteinuria, an increase in serum creatinine and a
decrease in creatinine clearance (I, II, IV) (Table 5). Enalapril and both doses of valsartan protected
against CsA-induced renal dysfunction (I, II). Icatibant had no effect on renal function during CsA
and enalapril administration (II). L-arginine had no significant effect on CsA-induced renal
dysfunction (IV).
5.4. Arterial function
The effects of CsA on arterial function were assessed to find out whether CsA-induced hypertension
and nephrotoxicity were related to arterial dysfunction. CsA severely impaired renal arterial
contractions induced by noradrenaline (III, IV), angiotensin II (III) and potassium chloride (IV)
(Table 6). Similarly, CsA impaired endothelium-dependent relaxation responses to acetylcholine
(III, IV) and endothelium-independent responses to sodium nitroprusside (III, IV) in renal arteries.
The effects of CsA on mesenteric arteries were less clear than in renal arteries: potassium chloride
contractions were significantly impaired by CsA (IV), but contractions induced by noradrenaline
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(III, IV) or angiotensin II (III) were not. Relaxation responses to acetylcholine were not significantly
affected by CsA in mesenteric arterial rings (III, IV). Sodium nitroprusside relaxations in mesenteric
arteries were impaired by CsA in study IV, but not significantly affected in study III.
Enalapril and both doses of valsartan improved the CsA-induced impairment of renal arterial
contractions to noradrenaline and angiotensin II as well as the sodium nitroprusside relaxations (III).
The higher dose of valsartan improved the acetylcholine response markedly, but the effects of
enalapril (P=0.06) or the lower dose of valsartan (P=0.24) did not reach significance. Icatibant had
no effect on arterial responses during CsA and enalapril administration (III). L-arginine protected
from the CsA-induced impairment of renal artery responses to potassium chloride, but did not affect
other contractile or relaxation responses significantly (IV).
5.5. Histology
5.5.1. Kidneys
Long-term CsA administration damaged one-third of glomeruli; the glomerular damage index was
about 8 times higher than in the control group (II) (Table 5). Pathological changes varied from a
slight mesangial matrix expansion to severe necrosis and capillary collapse (II, IV). Interstitial
fibrosis of striped pattern was apparent in the renal cortex of CsA-treated rats (II, IV). Atrophied
tubuli were surrounded by interstitial fibrotic tissue.
Enalapril and both doses of valsartan prevented all CsA-induced pathological renal changes (II).
Icatibant did not affect renal histology during CsA and enalapril treatment. L-arginine had no effect
on renal histology (IV).
5.5.2. Arteries
In small renal arterioles, CsA caused medial changes that ranged from minor smooth muscle cell
vacuolisation to massive smooth muscle and endothelial cell proliferation, leading to complete
occlusion of the vessel (II, IV) (Table 5). An increased amount of connective tissue surrounding the
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arterioles was also observed in CsA-treated rats. Large intrarenal arteries in the CsA group were
mostly normal; only a slight thickening of the adventitia was seen (II, IV). In study IV, interstitial
and perivascular abundance of leukocytes was detected.
The structure of the mesenteric arterial trunk, the first- and second-order branches and the smaller
arteries and arterioles of both the mesenteric arterial bed and the renal artery was mostly preserved
in the control group (IV).
CsA caused adventitial and perivascular fibrosis associated with the presence of leukocytes in small
arteries as well as in arterioles of the mesenteric bed, whereas medium-sized arteries were only
slightly affected (IV). The bigger arteries (mesenteric and renal artery) remained unaffected by CsA.
The medial and intimal layers were mostly normal in CsA-treated rats. However, focal medial
hypertrophy was present in some small arteries and arterioles of the mesenteric bed, sometimes
leading to occlusion of the vessel. L-arginine did not protect from CsA-induced morphological
damage to small arteries (IV).
CsA reduced the corrected area of the medial layer and its ratio to the mean diameter of the vessel in
the under 100 µm category by about 30% (IV). CsA affected neither the medial layer nor the medial
layer ratio to the diameter of the bigger vessels. Concomitant L-arginine tended to cut about half of
the CsA-induced decrease in medial hypotrophy in small vessels, but the effect was not significant
(P=0.2 vs. both the control and CsA group) (IV).
5.5.3. Heart
CsA administration caused histological damage to the hearts of SHR on high-sodium diet (I) (Table
5). The damage consisted of thickening of the vessel walls and fibrotic scars in the parenchyma.
Enalapril prevented damage to the arteries of the heart (I).
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5.6. Plasma renin activity and urinary kallikrein excretion
Plasma renin activity was measured to reflect the activity of RAS. The average PRA levels in
control rats were 0.5−0.8 ng angiotensin I/ml/h (I, II). CsA caused a 20 to 50-fold increase in PRA
(I, II). Concomitant enalapril or valsartan tended to further increase PRA during CsA treatment, but
the effect was not significant when compared with the group receiving CsA alone (I, II). Icatibant
had no effect on PRA during CsA and enalapril treatment (II).
Urinary kallikrein activity was assessed to reflect the renal kallikrein-kinin system activity. CsA
alone or combined with enalapril or valsartan had no effect on urinary kallikrein excretion (II).
Icatibant did not influence kallikrein excretion during CsA and enalapril treatment (II).
5.7. Tissue nitric oxide synthase expression and urinary cyclic guanosine 3',5'-monophosphate
Tissue NO synthase expression and urinary cGMP excretion were analysed to find out whether CsA
toxicity was related to dysfunction of the L-arginine−NO pathway. CsA alone or combined with
L-arginine had no effect on eNOS expression in the renal cortex, medulla, aorta or heart (IV). iNOS
expression was not detected in any of the study groups (IV). CsA alone or combined with L-arginine
had no effect on urinary cGMP excretion (IV).
5.8. Plasma total radical trapping parameter and urate, and urinary 8-isoprostaglandin F2α
To explore the hypothesis that CsA may induce oxidative stress, plasma urate concentration, TRAP
and urinary 8-isoprostaglandin F2α excretion were assessed. CsA alone or combined with L-arginine
had no effect on these variables (IV).
5.9. Cell cultures
The effect of long-term CsA treatment on cell viability was tested in cell culture. The viability of the
cultured aortic smooth muscle cells was preserved in the control group (IV): after the seven-day
culture, the number of aortic cells from the control group increased approximately 4-fold as
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compared with the beginning of the culture. In contrast, the six-week CsA administration in vivo
caused a clear decrease in the viability of the smooth muscle cells. After the seven-day culture, only
one plate out of four had a noticeable number of living cells.
Table 6. Summary of effects of CsA, enalapril, enalapril + icatibant, valsartan and L-arginine on
arterial function of SHR on high-sodium diet. NA, noradrenaline; Ang II, angiotensin II; KCl,
potassium chloride; Ach, acetylcholine; SNP, sodium nitropusside.
Renal arteries NA Ang II KCl Ach SNP
CsA ↓ ↓ ↓ ↓ ↓
+enalapril ↑ ↑ (↓ ) ↑
+icatibant ↔ ↔ ↔ ↔
+valsartan 3 mg/kg ↑ ↑ ↔ ↑
+valsartan 30 mg/kg ↑ ↑ ↑ ↑
+L-arginine ↔ ↑ ↔ ↔
Mesenteric arteries NA Ang II KCl Ach SNP
CsA ↔ ↔ ↓ ↔ ↔
+enalapril ↔ ↔ ↔ ↔
+icatibant ↔ ↔ ↔ ↔
+valsartan 3 mg/kg ↔ ↔ ↔ ↔
+valsartan 30 mg/kg ↑ ↔ ↔ ↔
+L-arginine ↔ ↔ ↔ ↔
↑ increased
↓ decreased
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6. DISCUSSION
Renal and cardiovascular effects of long-term administration of CsA were studied in SHR on high-
sodium diet during the developmental phase of hypertension. The animal model of SHR on high-
sodium diet was selected to overcome the resistance of normotensive rats to adverse renal and
cardiovascular effects of CsA. The present study evaluated the role of RAS, the renal kallikrein-
kinin system, the L-arginine−NO pathway and oxidative stress in CsA-induced renal and
cardiovascular effects. Furthermore, the effects of CsA on arterial function and morphological
changes were examined.
6.1. Relevance of the animal model used to toxicity of cyclosporine A in man
In CsA-treated patients, factors other than the drug may also have renal and cardiovascular effects.
These include rejection of the transplanted organ, the autoimmune disease against which CsA is
used and concomitant medications. Therefore, experimental models are needed to study the adverse
effects of CsA. However, species' differences in response to toxic effects of CsA have hampered
research (Porter et al. 1999; Taler et al. 1999).
In humans, the dietary intake of sodium in industrialised countries is several times greater than the
physiological need (Dyer et al. 1994). The excess sodium is a major risk factor for the development
of hypertension and end-organ damage (Mervaala et al. 1992; Dyer et al. 1994). Laboratory rats, in
contrast, are normally fed a diet containing sodium in an amount corresponding to their
physiological need. According to several studies, CsA-induced hypertension is sodium-sensitive
(Ryffel et al. 1986; Kaskel et al. 1987; Curtis et al. 1988; Curtis 1994; Mervaala et al. 1997).
Therefore, the differences in renal and cardiovascular effects of CsA observed between humans and
rats may, at least in part, be due to differences in sodium intake.
A decreased amount of excreted sodium was detected in CsA-treated rats at the end of the six-week
experiment. Even though sodium excretion remained unaffected by CsA in one study, this may be
seen as evidence of the sodium-retaining effect of chronic CsA treatment in SHR. However,
according to the pressure-natriuresis theory of Guyton et al. (1972), this reasoning is not logical. An
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increase in sodium intake may have an acute sodium-retaining effect, but to avoid chronic sodium
and water retention, the excess sodium excretion by kidneys is facilitated by an increase in blood
pressure (Guyton et al. 1972). Alternatively, the observed decrease in the amount of excreted
sodium with CsA may have been due to increased sodium stool loss, which has been observed in
rats (Devarajan et al. 1989). Thus, the present study does not greatly clarify the effects of CsA on
sodium handling in SHR.
CsA causes both hypertension and renal toxicity in patients. However, this is not the case in the
most frequently used animal model of CsA nephrotoxicity. Sodium-depleted Sprague Dawley rats
do not develop hypertension despite renal damage (Burdmann et al. 1995; Porter et al. 1999). In
contrast, in the presently used model of SHR on high-sodium diet, CsA caused nephrotoxicity
concomitantly with an increase in blood pressure. Some confounding factors may exist, such as the
effect of high-sodium intake and the pathophysiology underlying the development of hypertension
in SHR, which is still mostly unclear (Phillips 1999). However, the CsA-induced nephrotoxicity
with renal dysfunction, proteinuria, arteriolopathy, interstitial fibrosis and glomerular damage was
similar in character to that observed in patients (Mihatsch et al. 1988; Griffits et al. 1996; Andoh
and Bennett 1998). Thus, it is possible that clinical cardiovascular and renal toxicity of CsA in
humans is a combination of drug-induced hypertension and direct renal and vascular effects. The
present studies with this hypertensive model are, therefore, expected to shed some light on the
mechanisms of CsA toxicity in man.
6.2. Cyclosporine A-induced vascular changes
Long-term treatment of SHR with CsA caused an impairment of arterial function, including both
impaired relaxations and decreased contractile responses. This dysfunction was clear in renal but
less clear in mesenteric arteries. Both endothelium-dependent (acetylcholine) and endothelium-
independent (sodium nitroprusside) relaxations were impaired. Furthermore, CsA impaired
contractile responses of renal arteries to all test substances (noradrenaline, potassium chloride,
angiotensin II). These results show that CsA toxicity in SHR is related to arterial dysfunction. The
relationship between increased blood pressure and vascular dysfunction in different forms of
hypertension has been widely debated. The majority of evidence suggests that vascular dysfunction
52
is secondary to hypertension (McIntyre et al. 1999; Vapaatalo et al. 2000), although some studies
stress the importance of vascular dysfunction as a preceeding phenomenon (Jameson et al. 1993;
Taddei et al. 1996). CsA at therapeutically relevant concentrations is toxic to endothelial cells in
vitro (Zoja et al. 1986) and induces functional and morphological vascular damage in normotensive
rats without affecting blood pressure (Kim et al. 1996). CsA also interferes with intracellular
calcium homeostasis in vascular smooth muscle cells (Pfeilschifter and Ruegg 1987; Lo Russo et al.
1997; Meyer-Lehnert et al. 1997; Avdonin et al. 1999; Gordjani et al. 2000) and causes
vasoconstriction in vitro (Lanese et al. 1994; Epstein et al. 1998). Therefore, it is tempting to
speculate that the CsA-induced vascular dysfunction occurs first, and hypertension and renal
toxicity are, at least partly, secondary to the dysfunction.
CsA-induced hypertension was associated with endothelial, medial and adventitial damage to
intrarenal small arteries and arterioles and, to a lesser extent, to mesenteric resistance vessels. The
damage of resistance vessels was related with medial hypothrophy. CsA is known to cause
structural damage to intrarenal arteries and arterioles, while integrity of extrarenal vessels is mostly
preserved (Antonovych et al. 1988; Mihatsch et al. 1988; Andoh and Bennett 1998). Moreover,
experimental hypertension is usually associated with hypertrophy of the resistance vessels (Lee et
al. 1983). In this light, the CsA-induced medial hypotrophy was unexpected, and it seems likely that
the vascular damage was not solely due to hypertension but to some other effects of CsA in vascular
remodelling of the medial layer. One potential reason for this is apoptosis, which seems to be
involved in CsA-induced nephrotoxicity in normotensive rats during sodium deprivation (Thomas et
al. 1998). Accordingly, the decreased viability of the cultured aortic smooth muscle cells by CsA,
which was observed in the present study, might also have been due to apoptosis.
6.3. Renin-angiotensin system and renal kallikrein-kinin system in cyclosporine A toxicity
PRA is a widely used parameter to estimate the activity of the systemic RAS. Normally, high-
sodium intake physiologically depresses PRA. CsA, however, caused a substantial increase in PRA
in SHR during high-sodium diet. This finding is in agreement with several rat studies which
conclude that CsA increases PRA regardless of the sodium content of the diet (Burdmann et al.
1995; Abassi et al. 1996; Mervaala et al. 1997). However, variable effects of CsA on PRA in
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humans have been presented (Bantle et al. 1987; Myers et al. 1988; Mason et al. 1991; Julien et al.
1993).
The mechanism of the activation of RAS by CsA in SHR, in other animal models or in some
clinical settings is somewhat obscure. It may be due to a direct induction of renin excretion in
juxtaglomerular cells observed in vitro (Kurtz et al. 1988). On the other hand, CsA has
vasoconstrictive properties (Murray et al. 1985; Myers et al. 1988; Hansen et al. 1997; Andoh and
Bennett 1998) which may lead to reduction in blood supply to kidneys. Evidence exists that renin
secretion is tonically elevated in ischemic nephrons (Sealey et al. 1988). Therefore, it is possible
that increase in PRA is, at least partly, secondary to haemodynamic changes in kidneys. Some
observations with transplant patient have shown that PRA rises gradually after transplantation,
suggesting that activation of RAS is partly due to ischemic damage to kidneys (Taler et al. 1999).
An increase in blood pressure with CsA may also contribute to renal damage and a subsequent
increase in PRA in SHR. Taken together, CsA may, in fact, cause a vicious circle: RAS activation
by CsA reduces renal blood flow and induces local ischemia in kidneys that further increases renin
release and potentiates CsA toxicity. Thus, the rise in PRA may be both a cause and a consequence
of CsA-induced renal damage in SHR on high-sodium diet.
The effects of ACE inhibitors are usually somewhat weaker during high intake of sodium, when
RAS already is physiologically suppressed (Waeber et al. 1990). In the present study, however,
RAS antagonism with either enalapril or valsartan protected against the CsA-induced hypertension
effectively. This was probably due to activation of RAS by CsA. The effectiveness of enalapril and
valsartan in reducing blood pressure is consistent with several long-term clinical studies (Mourad et
al. 1993; Sennesael et al. 1995; Hannedouche et al. 1996; Del Castillo et al. 1998).
Angiotensin II has been proposed to have a major role in the development of CsA-induced renal
injury via induction growth factors and adhesion molecules (Pichler et al. 1995). ACE inhibitors
and AT1 receptor antagonists protect against renal injury without affecting blood pressure in the
sodium-depletion rat model of CsA toxicity (Burdmann et al. 1995; Andoh and Bennett 1998). An
ACE inhibitor and an AT1 receptor antagonist protected against renal injury in our hypertensive
model as well. The protection may have been due to directly reducing the local effects of
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angiotensin II, but prevention of CsA-induced hypertension may have also participated. The results
showed that RAS antagonism prevents CsA-induced renal injury, not only in blood pressure-
independent models of CsA toxicity, but also during concomitant rise in blood pressure. From the
data of the present study, however, it is not possible to differentiate the extent to which lowering of
blood pressure contributed to the renal protection.
Enalapril and valsartan protected against CsA-induced renal dysfunction, which was measured as
decreased creatinine clearance and increased serum creatinine concentration. The results are similar
to those of CsA-treated normotensive rats (Kaskel et al. 1987) and in diabetic patients
(Hannedouche et al. 1996). The findings are, however, in conflict with the effects of CsA in the
model of sodium deprivation, in which ACE inhibitors and AT1 receptor antagonists do not
normalise renal function, even though structural changes to the kidneys are protected against
(Burdmann et al. 1995; Andoh and Bennett 1998). The difference may be due to higher blood
pressure and glomerular perfusion pressure in SHR with high-sodium intake than in rats on sodium-
depleted diet, which had very low systemic blood pressure that was below the renal autoregulatory
range (Burdmann et al. 1995). It is also possible that preservation of kidney function by RAS
antagonists is at least partly due to prevention of glomerular damage rather than direct effects on
renal haemodynamics.
The present study also evaluated the role of the renal kallikrein-kinin system in long-term CsA
administration. Urinary kallikrein excretion is proposed to reflect renal glandular kallikrein activity
(Bönner and Marin-Grez 1981; Majima and Katori 1995). CsA had no effect on urinary kallikrein
excretion. Likewise, B2 receptor antagonist icatibant did not antagonise the beneficial effects of
ACE inhibition. Therefore, it seems that the renal kallikrein-kinin system does not have a crucial
role in CsA toxicity in this animal model. A study with normotensive rats suggested that in short-
term administration CsA may decrease the activity of the renal kallikrein system (Bompart et al.
1996). A similar finding in six-month CsA treatment in psoriasis patients suggested that suppression
of the renal kallikrein-kinin system may also have a role in long-term effects of CsA (Raman et al.
1998). However, increased renal kallikrein and bradykinin B2 receptor levels have been reported in
rats after long-term CsA administration (Wang et al. 1997). Physiological differences between man
and rat as well as duration of the experiment might explain the observed differences.
In summary, activation of RAS, but not the dysfunction of the renal kallikrein-kinin system, seems
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to be a major mechanism of CsA toxicity in this hypertensive animal model. Equally, inhibition of
RAS is effective  in protecting against CsA toxicity.
6.4. L-arginine−nitric oxide pathway and oxidative stress in cyclosporine A toxicity
The endothelial dysfunction detected in vitro could have been due to a defect in the L-arginine−NO
pathway induced by CsA. The long-term effects of CsA on the L-arginine−NO pathway were
evaluated by the expression of eNOS and iNOS as well as by urinary excretion of cGMP. CsA had,
however, no effect on urinary cGMP excretion or on eNOS and iNOS expression in the kidney,
heart and aorta. L-arginine, at a dose that has antagonised the toxic effects of CsA in normotensive
rats (Andoh et al. 1997), tended to have some beneficial effects during CsA administration in the
present study, but failed to reverse the CsA toxicity. According to literature, CsA induces eNOS
(Lopez-Ongil et al. 1996; Navarro-Antolin et al. 2000) and depresses iNOS in vitro (Dusting et al.
1999), but only some of the in vivo studies show similar results (Amore et al. 1995; Bobadilla et al.
1998). The present results are in agreement with those in vivo studies in which CsA did not affect
the L-arginine−NO pathway, even though L-arginine slightly attenuated CsA toxicity (Bobadilla et
al. 1994; Vaziri et al. 1998; Hansen et al. 1999). Thus, long-term toxic effects of CsA on
endothelial cells result in dysfunction, which seem to be mainly mediated by mechanisms other than
a defect in the L-arginine−NO pathway.
TRAP has been proposed to reflect the antioxidative status of plasma (Wayner et al. 1987). Urate
concentration of plasma is a major contributor to TRAP. Urinary excretion of 8-isoprostaglandin
F2α, which is a non-enzymatic product of free-radical catalysed peroxidation of arachidonic acid,
was used as a marker of oxidative products (Patrono and FitzGerald 1997; Kanji et al. 1999). CsA
did not affect TRAP, plasma urate concentration or urinary excretion of 8-isoprostaglandin F2α.
While some studies suggest that CsA may induce oxidative stress (Wang and Salahudeen 1994;
Wolf et al. 1994), its actual role in the development of the renal and cardiovascular toxicity is far
from clear (Buetler et al. 2000). The present results of unaltered indicators of oxidative stress
suggest that oxidative stress does not play a major part in long-term effects of CsA in this
hypertensive animal model. However, because the effects of antioxidant administration on CsA
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toxicity were not studied, and, analysis of plasma TRAP was performed at the end of the experiment
only, the participation of oxidative stress cannot be totally excluded.
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7. SUMMARY AND CONCLUSIONS
Clinically, CsA causes hypertension and nephrotoxicity, the latter of which are characterised by
renal dysfunction with a rise in serum creatinine and a decrease in creatinine clearance, and by
morphological damage with interstitial fibrosis and arteriolopathy. The exact mechanisms of CsA-
induced hypertension and nephrotoxicity are unknown. Renal and cardiovascular effects of long-
term administration of CsA were studied in SHR on high-sodium diet. The model was selected to
overcome the resistance of normotensive rats to adverse renal and cardiovascular effects of CsA.
The major findings and conclusions of this study are as follows:
1. CsA caused hypertension and nephrotoxicity that resemble those seen in CsA-treated patients.
2. Long-term CsA administration caused vascular dysfunction, which was more pronounced in
renal than in mesenteric arteries. The dysfunction included both impaired endothelium-
dependent and endothelium-independent relaxations and reduced contractile responses to
noradrenaline, potassium chloride and angiotensin II.
3. CsA toxicity was related to morphological damage in intrarenal arterioles and small arteries
and, to a lesser extent, in extrarenal resistance vessels.
4. Activation of RAS is an important mechanism of CsA toxicity in this hypertensive animal
model. Inhibition of RAS by ACE inhibitor or AT1 receptor antagonist protected against renal
and cardiovascular CsA-induced toxicity.
5. No major role was found for the renal kallikrein-kinin system, the L-arginine−NO pathway or
oxidative stress as primary causes of CsA toxicity.
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